126 related articles for article (PubMed ID: 36541645)
1. Seroconversion and persistence of neutralizing antibody response after yellow fever vaccination in patients with perinatally acquired HIV infection.
Martin C; Domingo C; Hainaut M; Delforge M; De Wit S; Dauby N
AIDS; 2023 Feb; 37(2):341-346. PubMed ID: 36541645
[TBL] [Abstract][Full Text] [Related]
2. Seroconversion and antibody persistence after yellow fever vaccination in people living with HIV: impact of baseline HIV viral load and yellow fever seropositivity.
Martin C; Florence E; Domingo C; Delforge M; De Wit S; Dauby N
J Travel Med; 2022 Dec; 29(8):. PubMed ID: 35285913
[TBL] [Abstract][Full Text] [Related]
3. Immunogenicity and duration of protection after yellow fever vaccine in people living with human immunodeficiency virus: a systematic review.
Martin C; Domingo C; Bottieau E; Buonfrate D; De Wit S; Van Laethem Y; Dauby N
Clin Microbiol Infect; 2021 Jul; 27(7):958-967. PubMed ID: 33813107
[TBL] [Abstract][Full Text] [Related]
4. Concomitant or sequential administration of live attenuated Japanese encephalitis chimeric virus vaccine and yellow fever 17D vaccine: randomized double-blind phase II evaluation of safety and immunogenicity.
Nasveld PE; Marjason J; Bennett S; Aaskov J; Elliott S; McCarthy K; Kanesa-Thasan N; Feroldi E; Reid M
Hum Vaccin; 2010 Nov; 6(11):906-14. PubMed ID: 20864814
[TBL] [Abstract][Full Text] [Related]
5. Immunogenicity and reactogenicity of yellow fever vaccine in people with HIV.
Motta E; Camacho LAB; Cunha M; de Filippis AMB; Lima SMB; Costa M; Pedro L; Cardoso SW; Cortes FH; Giacoia-Gripp CBW; Morata M; Nazer S; Moreira RI; de Oliveira Souza MC; Mendes YS; Souza Azevedo A; Dos Santos Alvez N; Grinsztejn B; Coelho LE
AIDS; 2023 Dec; 37(15):2319-2329. PubMed ID: 37650759
[TBL] [Abstract][Full Text] [Related]
6. Yellow fever vaccine for patients with HIV infection.
Barte H; Horvath TH; Rutherford GW
Cochrane Database Syst Rev; 2014 Jan; (1):CD010929. PubMed ID: 24453061
[TBL] [Abstract][Full Text] [Related]
7. Persistence of yellow fever virus-specific neutralizing antibodies after vaccination among US travellers.
Lindsey NP; Horiuchi KA; Fulton C; Panella AJ; Kosoy OI; Velez JO; Krow-Lucal ER; Fischer M; Staples JE
J Travel Med; 2018 Jan; 25(1):. PubMed ID: 30346562
[TBL] [Abstract][Full Text] [Related]
8. Short-Lived Immunity After 17DD Yellow Fever Single Dose Indicates That Booster Vaccination May Be Required to Guarantee Protective Immunity in Children.
Campi-Azevedo AC; Reis LR; Peruhype-Magalhães V; Coelho-Dos-Reis JG; Antonelli LR; Fonseca CT; Costa-Pereira C; Souza-Fagundes EM; da Costa-Rocha IA; Mambrini JVM; Lemos JAC; Ribeiro JGL; Caldas IR; Camacho LAB; Maia MLS; de Noronha TG; de Lima SMB; Simões M; Freire MDS; Martins RM; Homma A; Tauil PL; Vasconcelos PFC; Romano APM; Domingues CM; Teixeira-Carvalho A; Martins-Filho OA
Front Immunol; 2019; 10():2192. PubMed ID: 31616412
[TBL] [Abstract][Full Text] [Related]
9. Previous biological therapy and impairment of the IFN-γ/IL-10 axis are associated with low immune response to 17DD-YF vaccination in patients with spondyloarthritis.
Casagrande TZ; Costa-Rocha IAD; Gavi MBRO; Miyamoto ST; Martins PC; Serrano ÉV; Dinis VG; Machado KLLL; Gouvea SA; Caser LC; Campi-Azevedo AC; Teixeira-Carvalho A; Peruhype-Magalhães V; Bissoli MF; Gouvea MDPG; Lima SMB; Miranda EH; Trindade GF; Lyra DGP; Burian APN; Neto LFDSP; da Mota LMH; Martins-Filho OA; Valim V
Vaccine; 2022 Jul; 40(32):4580-4593. PubMed ID: 35728990
[TBL] [Abstract][Full Text] [Related]
10. Serum biomarker profile orchestrating the seroconversion status of patients with autoimmune diseases upon planned primary 17DD Yellow fever vaccination.
da Costa-Rocha IA; Machado KLLL; Campi-Azevedo AC; Teixeira-Carvalho A; Peruhype-Magalhães V; de Lima SMB; Miranda EH; Trindade GF; Casagrande TZ; Miyamoto ST; Deotti SC; Barbosa RVR; Rocha PCM; Serrano EV; Dinis VG; Gouvêa SA; Gavi MBRO; da Silva LB; Duque RH; Gianordoli APE; Bissoli MF; Gouvea MDPG; Pinto-Neto LFDS; Burian APN; Fantinato FFST; Pileggi GS; da Mota LMH; Valim V; Martins-Filho OA
Sci Rep; 2021 May; 11(1):10431. PubMed ID: 34001945
[TBL] [Abstract][Full Text] [Related]
11. Planned Yellow Fever Primary Vaccination Is Safe and Immunogenic in Patients With Autoimmune Diseases: A Prospective Non-interventional Study.
Valim V; Machado KLLL; Miyamoto ST; Pinto AD; Rocha PCM; Serrano EV; Dinis VG; Gouvêa SA; Dias JGF; Campi-Azevedo AC; Teixeira-Carvalho A; Peruhype-Magalhães V; da Costa-Rocha IA; de Lima SMB; Miranda EH; Trindade GF; Maia MLS; Gavi MBRO; da Silva LB; Duque RH; Gianordoli APE; Casagrande TZ; Oliveira KG; Moura BCDM; Nicole-Batista F; Rodrigues LC; Clemente TB; Magalhães ES; Bissoli MF; Gouvea MDPG; Pinto-Neto LFDS; Costa CZ; Giovelli RA; Brandão LR; Polito ETL; Koehlert IO; Borjaille BP; Pereira DB; Dias LH; Merlo DL; Genelhu LFF; Pretti FZ; Giacomin MDS; Burian APN; Fantinato FFST; Pileggi GS; da Mota LMH; Martins-Filho OA
Front Immunol; 2020; 11():1382. PubMed ID: 32765496
[TBL] [Abstract][Full Text] [Related]
12. Antibody responses to yellow fever vaccine in 9 to 11-month-old Malian and Ghanaian children.
Idoko OT; Mohammed N; Ansah P; Hodgson A; Tapia MD; Sow SO; Chowdhury PR; Niedrig M; Saathoff E; Kampmann B
Expert Rev Vaccines; 2019 Aug; 18(8):867-875. PubMed ID: 31269829
[No Abstract] [Full Text] [Related]
13. Duration of post-vaccination immunity against yellow fever in adults.
Collaborative group for studies on yellow fever vaccines
Vaccine; 2014 Sep; 32(39):4977-84. PubMed ID: 25090646
[TBL] [Abstract][Full Text] [Related]
14. Yellow fever neutralizing antibody seroprevalence proportion and titers in previously vaccinated adults with chronic kidney disease.
Cristina Martini Rodrigues C; Caroline Ribeiro Sales A; Marli Christovam Sartori A; de Souza Azevedo A; Maria Barbosa de Lima S; de Melo Picone C; Keiko Sato P; Nazareth Lara A; Takesaki Miyaji K; Sérgio Azevedo L; Caldin B; Camera Pierrotti L; Heloisa Lopes M
Vaccine; 2024 Apr; 42(11):2729-2732. PubMed ID: 38514353
[TBL] [Abstract][Full Text] [Related]
15. Prevalence and titers of yellow fever virus neutralizing antibodies in previously vaccinated adults.
Miyaji KT; Avelino-Silva VI; Simões M; Freire MD; Medeiros CR; Braga PE; Neves MA; Lopes MH; Kallas EG; Sartori AM
Rev Inst Med Trop Sao Paulo; 2017 Apr; 59():e2. PubMed ID: 28380113
[TBL] [Abstract][Full Text] [Related]
16. Immunogenicity and safety of primary fractional-dose yellow fever vaccine in autoimmune rheumatic diseases.
Tonacio AC; do Nascimento Pedrosa T; Borba EF; Aikawa NE; Pasoto SG; Filho JCRF; Sampaio Barros MM; Leon EP; Lombardi SCFS; Junior AM; Azevedo AS; Schwarcz WD; Fuller R; Yuki EFN; Ugolini Lopes MR; Rodrigues Pereira RM; Sampaio Barros PD; de Andrade DCO; de Medeiros-Ribeiro AC; de Moraes JCB; Shinjo SK; Miossi R; da Silva Duarte AJ; Lopes MH; Kallás EG; Almeida da Silva CA; Bonfá E
PLoS Negl Trop Dis; 2021 Nov; 15(11):e0010002. PubMed ID: 34843469
[TBL] [Abstract][Full Text] [Related]
17. Differential gene expression of cytokines, receptors, and miRNAs in individuals living with HIV-1 and vaccinated against yellow fever.
Macieira KV; Caetano DG; De Lima SMB; Wagner Giacoia-Gripp CB; Côrtes FH; Da Silva Cazote A; De Souza Azevedo Soares A; Dos Santos Alves N; De Souza Borges Quintana M; Costa M; Brandão LGP; De Andrade MM; Grinsztejn B; Coelho LE; De Almeida DV
Mol Immunol; 2023 Dec; 164():58-65. PubMed ID: 37952362
[TBL] [Abstract][Full Text] [Related]
18. Duration of post-vaccination humoral immunity against yellow fever in children.
de Noronha TG; de Lourdes de Sousa Maia M; Geraldo Leite Ribeiro J; Campos Lemos JA; Maria Barbosa de Lima S; Martins-Filho OA; Campi-Azevedo AC; da Silva Freire M; de Menezes Martins R; Bastos Camacho LA;
Vaccine; 2019 Nov; 37(48):7147-7154. PubMed ID: 31590934
[TBL] [Abstract][Full Text] [Related]
19. Detection of anti-yellow fever virus immunoglobulin m antibodies at 3-4 years following yellow fever vaccination.
Gibney KB; Edupuganti S; Panella AJ; Kosoy OI; Delorey MJ; Lanciotti RS; Mulligan MJ; Fischer M; Staples JE
Am J Trop Med Hyg; 2012 Dec; 87(6):1112-5. PubMed ID: 23109371
[TBL] [Abstract][Full Text] [Related]
20. Immunogenicity of Fractional-Dose Vaccine during a Yellow Fever Outbreak - Final Report.
Casey RM; Harris JB; Ahuka-Mundeke S; Dixon MG; Kizito GM; Nsele PM; Umutesi G; Laven J; Kosoy O; Paluku G; Gueye AS; Hyde TB; Ewetola R; Sheria GKM; Muyembe-Tamfum JJ; Staples JE
N Engl J Med; 2019 Aug; 381(5):444-454. PubMed ID: 29443626
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
